The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

This year a clinical trial will test a drug combination designed to bring lasting relief for people with panic disorder – a condition that can upend daily life and be notoriously difficult to treat.

At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...

Gilead Sciences Inc. (NASDAQ: GILD) on Monday shared topline results from the Phase 3 ARTISTRY-2 trial. The trial evaluated the treatment responses of adults with HIV ...